Developing a Universal Staphylococcus aureus Vaccine: Why Aren’t We There Yet?
|Amita Joshi* and Tessie B. McNeely|
|Vaccine Basic Research, Merck Research Labs, West Point, PA 19486, USA|
|*Corresponding Author :||Amita Joshi, PhD
Vaccine Basic Research
Merck Research Labs WP26-252 West Point
PA 19486, USA
E-mail: [email protected]
|Received July 04, 2013; Accepted August 24, 2013; Published August 28, 2013|
|Citation: Joshi A, McNeely TB (2013) Developing a Universal Staphylococcus aureus Vaccine: Why Aren’t We There Yet? Intern Med 3:126. doi:10.4172/2165-8048.1000126|
|Copyright: © 2013 Joshi A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
This review discusses several aspects of vaccine development efforts for Staphylococcus aureus. While several vaccines have shown efficacy in pre-clinical models, a potent and successful S aureus vaccine still eludes us. This review captures the historical literature on S. aureus vaccine development and discusses the results of major clinical trials in the field. Here we discuss important new insights into immunological mechanisms of protection from extracellular bacterial infections and shed light on important pre-clinical and clinical findings that establish a correlation between S. aureus infections and lack of cell mediated immunity. We attempt to provide an immunological explanation for the reasons behind the failure of prior S. aureus vaccines and provide insight into the rational design of a universal vaccine for S. aureus infections.